![Table 1 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 1 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/2-Table1-1.png)
Table 1 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) - Bird - 2009 - UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) - Bird - 2009 -](https://onlinelibrary.wiley.com/cms/asset/ffecafce-1521-4793-a94e-a59e10701706/bjh_7807_f1.gif)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) - Bird - 2009 -
![Exploring the sequence features determining amyloidosis in human antibody light chains | Scientific Reports Exploring the sequence features determining amyloidosis in human antibody light chains | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-93019-9/MediaObjects/41598_2021_93019_Fig3_HTML.png)
Exploring the sequence features determining amyloidosis in human antibody light chains | Scientific Reports
![Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS](https://www.pnas.org/content/117/1/292/F1.large.jpg)
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS
![Table 2 from Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. | Semantic Scholar Table 2 from Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c28d1869d8b2fbdcbec72aba911a0739211e7e46/7-Table2-1.png)
Table 2 from Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. | Semantic Scholar
![Frontiers | Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype | Immunology Frontiers | Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype | Immunology](https://www.frontiersin.org/files/Articles/508073/fimmu-11-00319-HTML/image_m/fimmu-11-00319-g001.jpg)
Frontiers | Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype | Immunology
![Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study | Journal of Experimental & Clinical Cancer Research Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-016-0324-0/MediaObjects/13046_2016_324_Fig1_HTML.gif)
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study | Journal of Experimental & Clinical Cancer Research
Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease
![PDF) The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma PDF) The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma](https://www.researchgate.net/publication/343542653/figure/fig2/AS:934204644806656@1599743152174/Distribution-of-light-chain-ratios-of-A-kappa-dominance-and-B-lambda-dominance_Q320.jpg)
PDF) The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma
![Percentage of immunoglobulin heavy chain V-gene family and kappa/lambda... | Download Scientific Diagram Percentage of immunoglobulin heavy chain V-gene family and kappa/lambda... | Download Scientific Diagram](https://www.researchgate.net/profile/Jianqing-Xu-2/publication/257530328/figure/fig1/AS:339857105801223@1458039656783/Percentage-of-immunoglobulin-heavy-chain-V-gene-family-and-kappa-lambda-light-chain.png)
Percentage of immunoglobulin heavy chain V-gene family and kappa/lambda... | Download Scientific Diagram
![COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria - Hines - 2021 - Clinical Case Reports - Wiley Online Library COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria - Hines - 2021 - Clinical Case Reports - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/298bf1c8-2316-4ca1-8b12-b7abe2f07bce/ccr34636-fig-0003-m.jpg)
COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria - Hines - 2021 - Clinical Case Reports - Wiley Online Library
Full article: The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan](https://www.ccij-online.org/articles/2019/8/5/images/ClinCancerInvestigJ_2019_8_5_177_269264_t3.jpg)
The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan
![The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan](https://www.ccij-online.org/articles/2019/8/5/images/ClinCancerInvestigJ_2019_8_5_177_269264_t4.jpg)
The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan
![The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan](https://www.ccij-online.org/articles/2019/8/5/images/ClinCancerInvestigJ_2019_8_5_177_269264_f2.jpg)